Infectious Disease Therapeutics Market Share and Forecast
Infectious Disease Therapeutics Market Growth, Size, Trends Analysis- By Infection, By Drug Class, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Sep-2025 | Report ID: HLCA25283 | Pages: 1 - 240 | Formats*: |
| Category : Healthcare | |||
Infectious Disease Therapeutics Market Introduction and Overview
According to SPER Market Research, the Global Infectious Disease Therapeutics Market is estimated to reach USD 351.4 billion by 2034 with a CAGR 3.74%.
The report includes an in-depth analysis of the Global Infectious Disease Therapeutics Market, including market size and trends, product mix, Applications, and supplier analysis. The global Infectious Disease Therapeutics Market was valued at USD 243,409.1 million in 2024 and is expected to grow at a CAGR of over 3.74% from 2025 to 2034. The anti-infective market is expanding due to rising global health threats, drug-resistant infections, and growing awareness of disease prevention. Chronic conditions like HIV/AIDS, hepatitis, and tuberculosis continue to drive demand for effective treatments. Technological advancements in diagnostics, immunotherapies, and personalized medicine further improve treatment outcomes. Increasing global travel, urbanization, and climate change are contributing to the spread of infectious diseases, intensifying the need for robust anti-infective solutions. Outbreaks of diseases such as Ebola and Zika emphasize the importance of rapid-response therapies. The COVID-19 pandemic highlighted the urgent need for targeted antivirals to quickly manage and contain severe global infections.
By Infection:
Viral infections lead the anti-infective market, driven by the rising prevalence of illnesses such as influenza, HIV, hepatitis, COVID-19, and monkeypox. Globalization, urbanization, and climate change contribute to the rapid spread of these diseases, increasing demand for antiviral drugs and vaccines. Advances in biotechnology, RNA-based therapies, and monoclonal antibodies are enhancing treatment options. Meanwhile, parasitic infections represent the fastest-growing segment, fueled by increasing cases, drug resistance, and global health initiatives. Efforts target diseases like malaria and leishmaniasis, especially in high-burden regions, with improved access and pharmaceutical innovation supporting continued market growth.
By Drug Class:
Vaccines hold a leading position in the anti-infective agents market, driven by rising disease prevalence, increased public awareness, and robust government immunization programs. Demand is fueled by emerging and re-emerging infections like COVID-19, influenza, HPV, and RSV. Innovations in mRNA, recombinant, and vector-based technologies are enhancing vaccine efficacy and accelerating development. Growing R&D investment, global health partnerships, and regulatory support further boost the market. Meanwhile, the antiparasitic drugs segment is expanding rapidly, especially in regions with high disease burdens, supported by next-generation drug development, improved access, and international eradication efforts.
By Distribution Channel:
Hospital pharmacies dominate the anti-infective market, driven by the rising global rate of hospitalizations. These pharmacies are integrated within large healthcare institutions that provide advanced care, specialized units, and quicker reimbursement through insurance, making them the preferred choice for treating severe infections. Meanwhile, the other pharmacy segment is rapidly expanding, driven by the rise of online pharmacies offering improved accessibility and convenience. E-commerce platforms allow direct delivery of medications, reducing reliance on traditional retail. Regulatory backing and growing internet access support this shift, especially in underserved regions needing antiparasitic, antibiotic, and antiviral treatments.
Regional Insights:
North America leads the infectious disease therapeutics market, driven by a high burden of bacterial, viral, and parasitic infections and widespread use of antibiotics, antivirals, and antiparasitic drugs. Increased adoption of vaccines and monoclonal antibodies is enhancing treatment effectiveness. Hospital-based care remains dominant, while demand is growing across retail and online pharmacies. In Asia Pacific, the market is expanding rapidly due to rising infection rates and strengthened healthcare systems. Countries like China, India, and Japan are at the forefront, supported by government initiatives and increased local production of antibiotics and vaccines.
Market Competitive Landscape:
The Infectious Disease Therapeutics Market is highly consolidated. Some of the market key players are AbbVie, AstraZeneca, Bayer AG, B. Braun SE, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Mankind Pharma, Merck & Co., Inc., Novartis AG, Pfizer Inc.
Recent Developments:
In February 2025, AbbVie and Pfizer’s drug Emblaveo was approved for use with an antibiotic to treat abdominal infections in adults.
In March 2024, AbbVie acquired Landos Biopharma, gaining NX-13, a Phase 2 oral treatment for ulcerative colitis with infectious disease relevance.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Infection, By Drug Class, By Distribution Channel |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | AbbVie, AstraZeneca, Bayer AG, B. Braun SE, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Mankind Pharma, Merck & Co., Inc., Novartis AG, Pfizer Inc. |
- Global Infectious Disease Therapeutics Market Size (FY 2021-FY 2034)
- Overview of Global Infectious Disease Therapeutics Market
- Segmentation of Global Infectious Disease Therapeutics Market By Infection (Bacterial Infections, Viral Infections, Fungal Infections, Parasitic Infections)
- Segmentation of Global Infectious Disease Therapeutics Market By Drug Class (Antibacterials, Antivirals, Antifungals, Antiparasitic Drugs, Vaccines, Others)
- Segmentation of Global Infectious Disease Therapeutics Market By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
- Statistical Snap of Global Infectious Disease Therapeutics Market
- Expansion Analysis of Global Infectious Disease Therapeutics Market
- Problems and Obstacles in Global Infectious Disease Therapeutics Market
- Competitive Landscape in the Global Infectious Disease Therapeutics Market
- Details on Current Investment in Global Infectious Disease Therapeutics Market
- Competitive Analysis of Global Infectious Disease Therapeutics Market
- Prominent Players in the Global Infectious Disease Therapeutics Market
- SWOT Analysis of Global Infectious Disease Therapeutics Market
- Global Infectious Disease Therapeutics Market Future Outlook and Projections (FY 2025-FY 2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Infectious Disease Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Infectious Disease Therapeutics Market
7. Global Infectious Disease Therapeutics Market, By Infection, (USD Million) 2021-2034
- 7.1. Bacterial Infections
- 7.2. Viral Infections
- 7.2.1. Human Immunodeficiency Virus (HIV/AIDS)
- 7.2.2. Hepatitis (Hepatitis B, Hepatitis C)
- 7.2.3. Influenza
- 7.2.4. Others
- 7.3. Fungal Infections
- 7.4. Parasitic Infections
8. Global Infectious Disease Therapeutics Market, By Drug Class, (USD Million) 2021-2034
- 8.1. Antibacterials
- 8.2. Antivirals
- 8.3. Antifungals
- 8.4. Antiparasitic Drugs
- 8.5. Vaccines
- 8.6. Others
9. Global Infectious Disease Therapeutics Market, By Distribution Channel, (USD Million) 2021-2034
- 9.1. Hospital Pharmacies
- 9.2. Retail Pharmacies
- 9.3. Others
10. Global Infectious Disease Therapeutics Market, (USD Million) 2021-2034
- 10.1. Global Infectious Disease Therapeutics Market Size and Market Share
11. Global Infectious Disease Therapeutics Market, By Region, 2021-2034 (USD Million)
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
12. Company Profile
- 12.1. AbbVie
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. AstraZeneca
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. Bayer AG
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4.B. Braun SE
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. Boehringer Ingelheim International GmbH
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. Bristol-Myers Squibb
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. F .Hoffmann-La Roche Ltd
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Gilead Sciences, Inc.
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
- 12.9. Mankind Pharma
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Merck & Co., Inc.
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
- 12.11. Novartis AG
- 12.11.1. Company details
- 12.11.2. Financial outlook
- 12.11.3. Product summary
- 12.11.4. Recent developments
- 12.12. Pfizer Inc.
- 12.12.1. Company details
- 12.12.2. Financial outlook
- 12.12.3. Product summary
- 12.12.4. Recent developments
- 12.13. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Infectious Disease Therapeutics Market is projected to reach USD 351.4 billion by 2034, growing at a CAGR of of 3.74% during the forecast period.
Infectious Disease Therapeutics Market grew in Market size from 2025. The Market is expected to reach USD 351.4 billion by 2034, at a CAGR of 3.74% during the forecast period.
Infectious Disease Therapeutics Market CAGR of 3.74% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Infectious Disease Therapeutics Market size is USD 351.4 billion from 2025 to 2034.
Infectious Disease Therapeutics Market is covered By Infection, By Drug Class, By Distribution Channel
The North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa is the highest Market share in the Infectious Disease Therapeutics Market.
AbbVie, AstraZeneca, Bayer AG, B. Braun SE, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Mankind Pharma, Merck & Co., Inc., Novartis AG, Pfizer Inc.
The report includes an in-depth analysis of the Global Infectious Disease Therapeutics Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
